Format

Send to

Choose Destination
Ann Hematol. 2018 Oct;97(10):1851-1857. doi: 10.1007/s00277-018-3387-5. Epub 2018 Jun 11.

Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study.

Author information

1
Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea.
2
Department of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea.
3
Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
4
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
5
Department of Hematology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
6
Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
7
Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, South Korea.
8
Division of Hematology/Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea.
9
Department of Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea.
10
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. csuh@amc.seoul.kr.
11
Department of Hematology-Oncology, Asan Medical Center University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. csuh@amc.seoul.kr.

Abstract

Both-side synchronous involvement has been reported to account for 7-24% of ocular adnexal marginal zone lymphoma (OAML). We conducted a retrospective analysis to identify the clinical features and treatment outcomes of synchronous bilateral OAML (SB-OAML) by treatment modality. We analyzed patients with a histologic diagnosis of SB-OAML, excluding metachronous bilateral involved OAML. We enrolled a total of 95 patients for this analysis, 36 males and 59 females; the median patient age was 42 years (range 16-77 years). Eleven (11.6%) patients had been treated with chemotherapy or chemo-immunotherapy (eight R-CVP, two CVP, and one R-CHOP). The median number of treatments was 6 (range 6-8); there were 9 complete responses (CRs; 81.8%) and 2 partial responses (PRs; 18.2%). Nearly all patients (88.4%) received radiotherapy in both eyes, and the median radiation dose was 27 Gy (range 20-40 Gy) to each eye; 68 CRs (80.9%) and 14 PRs (16.7%) were achieved. Ten-year progression-free survival (PFS) and overall survival (OS) rates were 79.8 and 91.1%, respectively. Radiotherapy continued to be an independent prognostic marker, with the hazard of progression (P = 0.036). Eleven patients (13.1%) had surgery for cataract treatment during follow-up, and patients who received low-dose radiation (< 30.3 Gy) experienced fewer cataract operations. SB-OAML was predominantly observed in young females, and they had good response and prognosis regardless of treatment modalities. Low-dose radiotherapy to both eyes showed a tendency of longer PFS than did chemotherapy and could decrease cataract operations.

KEYWORDS:

Bilateral; Ocular adnexal marginal zone lymphoma; Synchronous

PMID:
29947974
DOI:
10.1007/s00277-018-3387-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center